𝔖 Bobbio Scriptorium

✦ LIBER ✦

Limited Usefulness of the Modified Academic Research Consortium Stent Thrombosis Definition for Clinical Trials

✍ Scribed by Matthias E. Pfisterer; Raban Jeger; Christoph A. Kaiser

Book ID: 119289392
Publisher: American College of Cardiology
Year: 2011
Tongue: English
Weight: 87 KB
Volume: 4
Category: Article
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2011.08.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Standardized Endpoint Definitions for Tr

Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical Trials: A Consensus Report From the Valve Academic Research Consortium

✍ Martin B. Leon; Nicolo Piazza; Eugenia Nikolsky; Eugene H. Blackstone; Donald E. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 902 KB

Risk of Thrombosis With the Use of Sirol

Risk of Thrombosis With the Use of Sirolimus-Eluting Stents for Percutaneous Coronary Intervention (from Registry and Clinical Trial Data)

✍ Anthony A. Bavry; Dharam J. Kumbhani; Thomas J. Helton; Deepak L. Bhatt 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 173 KB

COMPARISON OF CLINICAL UTILITY BETWEEN N

COMPARISON OF CLINICAL UTILITY BETWEEN NEW AND OLD BLEEDING CRITERIA : A PROSPECTIVE STUDY OF EVALUATION FOR THE BLEEDING ACADEMIC RESEARCH CONSORTIUM DEFINITION OF BLEEDING IN PATIENTS WITH UNDERGOING PERCUTANEOUS INTERVENTION

✍ Choi, Jae Hyuk; Park, Kyungil; Kim, Young-dae 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Can multiparametric magnetic resonance i

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 415 KB